AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

11:07pm - World Lung Cancer Conference - Abstract No #MA17.04

Related indices

STOXX Europe 600 Index (EUR) , FTSE 100

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ASTRAZENECA : Healthy operational momentum sustained in Q2

July 26, 2024 at 05:10 pm

'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot

February 09, 2023 at 03:04 pm

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

162.03USD

Average target price

184.20USD

Spread / Average Target

+13.69%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 16:35:10 10/09/2024 BST			5-day change	1st Jan Change
12,406.00 ^GBX	-2.41%		-5.94%	+17.04%

09-10	AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	MT
09-10	European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	MT

AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	09-10	MT
European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	09-10	MT
British Equities Retreat on Fresh UK Labor Market Data	09-10	MT
European shares drop while BMW skids into reverse	09-10	AN
Sophia Genetics Partners with AstraZeneca on Expanding Global Access to Liquid Biopsy Testing Option	09-10	MT
ASTRAZENECA : Stifel confirms its recommendation on the stock	09-10	CF
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing	09-10	CI
ASTRAZENECA : disappointing test, Oddo BHF remains 'neutral	09-10	CF
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	09-10	ZD
Pascal Soriot, CEO of AstraZeneca : New lung cancer treatment shows two-month improvement in survival	09-10	MT
Four steps back, one step forward	09-10
ASTRAZENECA : UBS remains Sell on clinical trial results	09-10	CF
Shares mixed as investors await US inflation	09-10	AN
AstraZeneca Shares Slump After Cancer Drug Misses Key Target	09-10	DJ
AstraZeneca share price falls, clinical trial unconvincing	09-10	CF
AstraZeneca shares drop as lung cancer drug trial fails to improve survival	09-10	RE
European stocks mixed before eyes turn stateside	09-10	AN
FTSE 100 falls as AstraZeneca weighs; slowing wage growth cements rate cut bets	09-10	RE
European shares hold ground as AstraZeneca drags, tech shares rise	09-10	RE
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Shows Promising Response Rates in Combination With Imfinzi	09-10	MT
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Fails to Exhibit Significant Overall Survival Rate	09-10	MT
Health Care Up on Cyclical Bias -- Health Care Roundup	09-09	DJ
Transcript : AstraZeneca PLC - Special Call	09-09
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival	09-09	RE
The market burns its idols	09-09

AstraZeneca PLC

Equities

AZN